JP2025504002A5 - - Google Patents

Info

Publication number
JP2025504002A5
JP2025504002A5 JP2024544751A JP2024544751A JP2025504002A5 JP 2025504002 A5 JP2025504002 A5 JP 2025504002A5 JP 2024544751 A JP2024544751 A JP 2024544751A JP 2024544751 A JP2024544751 A JP 2024544751A JP 2025504002 A5 JP2025504002 A5 JP 2025504002A5
Authority
JP
Japan
Prior art keywords
cells
composition
flow rate
centrifugal force
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061510 external-priority patent/WO2023147515A1/en
Publication of JP2025504002A publication Critical patent/JP2025504002A/ja
Publication of JP2025504002A5 publication Critical patent/JP2025504002A5/ja
Pending legal-status Critical Current

Links

JP2024544751A 2022-01-28 2023-01-27 細胞組成物を製造する方法 Pending JP2025504002A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263304502P 2022-01-28 2022-01-28
US63/304,502 2022-01-28
US202363438764P 2023-01-12 2023-01-12
US63/438,764 2023-01-12
PCT/US2023/061510 WO2023147515A1 (en) 2022-01-28 2023-01-27 Methods of manufacturing cellular compositions

Publications (2)

Publication Number Publication Date
JP2025504002A JP2025504002A (ja) 2025-02-06
JP2025504002A5 true JP2025504002A5 (cg-RX-API-DMAC7.html) 2026-02-04

Family

ID=85505702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544751A Pending JP2025504002A (ja) 2022-01-28 2023-01-27 細胞組成物を製造する方法

Country Status (6)

Country Link
US (1) US20250101379A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469563A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504002A (cg-RX-API-DMAC7.html)
KR (1) KR20240137075A (cg-RX-API-DMAC7.html)
CN (1) CN119013393A (cg-RX-API-DMAC7.html)
WO (1) WO2023147515A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250215382A1 (en) * 2023-12-31 2025-07-03 Trenchant BioSystems, Inc. Functionally closed cell processing system
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539794A (en) 1967-09-12 1970-11-10 American Cyanamid Co Self-contained chemiluminescent lighting device
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5171081A (en) 1992-05-29 1992-12-15 Pita Joe W Chemiluminescent reactive vessel
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
CA2164226C (en) 1993-06-04 2011-02-08 Carl H. June Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
JP2012507555A (ja) 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション 稀少疾患の治療における抗cs1抗体の使用
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
MA33256B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗fcrh5抗體
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
BR112017005766B1 (pt) 2014-09-22 2022-10-25 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
AU2015357535B2 (en) 2014-12-05 2020-05-14 Eureka Therapeutics, Inc. Antibodies targeting G-protein coupled receptor and methods of use
DK3227339T3 (da) 2014-12-05 2022-01-10 Memorial Sloan Kettering Cancer Center Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
AU2017229635A1 (en) * 2016-03-07 2018-09-20 Hitachi Chemical Advanced Therapeutics Solutions, LLC A closed system for labelling and selecting live cells
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
US20190030073A1 (en) 2016-12-02 2019-01-31 Cartesian Therapeutics, Inc. Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
EP3572427B1 (en) 2017-01-23 2025-06-25 CRAGE medical Co., Limited Bcma-targeting antibody and use thereof
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
SG11201910131YA (en) 2017-05-12 2019-11-28 Scinogy Products Pty Ltd Compact reverse flow centrifuge system
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
EP3743214B1 (en) 2018-01-22 2025-08-20 Scinogy Products Pty Ltd System, method and controller for recovery of concentrated particles suspended in fluid
AU2019214183B2 (en) 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
BR112020018049A2 (pt) 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
CA3111384A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
PE20211915A1 (es) 2018-12-01 2021-09-28 Allogene Therapeutics Inc Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso
BR112022008522A2 (pt) 2019-11-05 2022-07-26 Celgene Corp Usos de receptores de antígeno quimérico anti-bcma
PE20221757A1 (es) 2020-02-24 2022-11-11 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas
WO2021252898A1 (en) * 2020-06-12 2021-12-16 Pact Pharma, Inc. Compositions and methods of manufacturing autologous t cell therapies

Similar Documents

Publication Publication Date Title
US20240191188A1 (en) Methods for culturing cells and kits and apparatus for same
US12351825B2 (en) Soluble antibody complexes for T cell or NK cell activation and expansion
US20210115401A1 (en) Methods and Materials for the Generation of Regulatory T Cells
US20190136186A1 (en) Methods for culturing cells and kits and apparatus for same
JP2022512872A5 (cg-RX-API-DMAC7.html)
WO2016166568A1 (en) Methods, kits and apparatus for expanding a population of cells
US20260132201A1 (en) METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCY
WO2018022694A1 (en) Simultaneous separation and activation of t cells from blood products with subsequent stimulation to expand t cells
CN113966394A (zh) 产生遗传修饰的t细胞的方法
AU779289B2 (en) Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression
CN112912103A (zh) 多价蛋白质复合物
RU2777989C2 (ru) Олигомерные реагенты в виде частиц и способы их применения
HK40067810B (en) Methods for enhancing tcr alpha beta+ cell depletion efficiency
HK40067810A (en) Methods for enhancing tcr alpha beta+ cell depletion efficiency
CN111793603A (zh) 一种新的有效地激活和扩增t细胞的方法
HK40061392A (en) METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
NZ742136B2 (en) Improved methods for manufacturing adoptive cell therapies